10 Worst ARK Stocks To Buy According To Short Sellers

4. Verve Therapeutics, Inc. (NASDAQ:VERV)

Short Interest as % of  Shares Outstanding: 19.20%

Number of Hedge Fund Investors In Q2 2024: 26

Ark Invest’s Q2 2024 Stake: $14.3 million

Verve Therapeutics, Inc. (NASDAQ:VERV) is a pre commercial stage biotechnology company that is developing gene editing treatments to help manage cholesterol levels and treat heart diseases. The firm’s fate revolves around its three key treatments under development VERVE 101, VERVE 102, and VERVE 201. Among these, VERVE 101 was the most promising up until April 2024 when Verve Therapeutics, Inc. (NASDAQ:VERV)’s stock tanked by a whopping 35% when data showed that the VERVE 101 had presented severe adverse effects including low platelet count. In August, Verve Therapeutics, Inc. (NASDAQ:VERV) shared an update for the drug, noting that the abnormality appeared to stem from liquid nanoparticles in the drug. Trial enrollments are paused, and the narrative has now shifted to VERVE 102, which is currently in clinical trial, and VERVE 201 which is currently preparing for phase 1b trials later this year. VERVE 102’s trial data should be available next year, which significantly pushes Verve Therapeutics, Inc. (NASDAQ:VERV)’s ability to potentially generate revenue in the future.